Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma

Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma

(2019) Thomas J. Kaley et al.   JOURNAL OF NEURO-ONCOLOGY

Lomustine and Bevacizumab in Progressive Glioblastoma

(2017) Wolfgang Wick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alkylphospholipids – A Promising Class of Chemotherapeutic Agents with a Broad Pharmacological Spectrum

(2016) Juliana De Almeida Pachioni et al.   JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms

(2014) William D. Figg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

(2014) P. Y. Wen et al.   NEURO-ONCOLOGY

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02

(2012) E. Q. Lee et al.   NEURO-ONCOLOGY

Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma

(2011) Kenneth L. Pitter et al.   PLoS One

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE